Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SUNITINIB MALATE
- A Bioequivalence Study of Sunitinib Malate Capsules.
- Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
- Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
- A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
- A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
- Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)
- Losartan + Sunitinib in Treatment of Osteosarcoma
- Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
- Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
- A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
- Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
- A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma
- Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
- Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
- Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
- A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
- Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
- Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
- Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
- A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
- A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
- Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
- Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
- A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
- Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
- A Phase 1b Trial in Patients With Renal Cell Cancer
- Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
- Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
- Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
- Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
- Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer
- Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
- Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
- Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
- Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
- Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
- Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer
- Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
- Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients
- Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
- GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line
- Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
- Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer
- Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
- Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer
- Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer
- Sunitinib Malate in Treating Patients With Small Cell Lung Cancer
- Sunitinib Malate in Treating Patients With Kidney Cancer
- Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
- Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
- Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
- Sunitinib Malate in Refractory Germ Cell Tumors
- Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases
- Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
- Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
- A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
- Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors
- Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
- Study In Patients With Kidney Cancer Treated With Sutent
- Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab
- Sunitinib Non Small Cell Lung Cancer Patients Over 70
- Sunitinib in Certain Subtypes of Soft Tissue Sarcomas
- Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
- AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib
- Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
- Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
- Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
- Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
- Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
- Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
- Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
- Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
- Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
- Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
- Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
- Sutent + Taxol for Advanced Esophageal Cancer
- Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
- Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
- Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
- Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
- Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
- Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
- Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
- Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
- Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
- Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
- Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
- Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome
- Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy
- Study Of Sunitinib With Capecitabine In Breast Cancer
- Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer
- Clinical Trial of Sutent to Treat Metastatic Melanoma
- Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
- Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer
- Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
- A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
- Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
- Phase II Sunitinib Prog Met AIPC
- Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors
- Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer
- Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
- Bevacizumab in Multiple Phase I Combinations
- Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
- Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
- Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
- Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma
- Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
- Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
- Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- Sunitinib in Treating Patients With Relapsed Multiple Myeloma
- Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
- Sunitinib in Treating Patients With Recurrent Malignant Gliomas
- Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
- Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
- Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)
- Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
- Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
- Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
- Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
- Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
- Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer
- Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
- Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
- Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
- Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
- Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
- Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
- A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)
- Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
- Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
- Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
- Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
- A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
- A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
- Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
- A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer
- Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
- Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy
- Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
- Perifosine + Sunitinib Malate for Patients With Advanced Cancers
- Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
- Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
- Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer
- Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma
- Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
- Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery
- Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
- Sunitinib in Treating Young Patients With Refractory Solid Tumors
- Sunitinib in Treating Patients With Idiopathic Myelofibrosis
- Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
- Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
- Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
- A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
- Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
- Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
- Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
- Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
- Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
- Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
- Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
- Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)
- Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
- Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
- Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
Clinical trials list
click for details